Joint Commission on Accreditation of Healthcare Organizations

The Joint Commission on Accreditation of Healthcare Organizations was a nonprofit health care and hospital accreditation body that in 1999 approved mandatory standards for pain assessment and treatment. Its decision gave institutional force to the emerging view of pain as a clinical priority, while creating an opening for Purdue Pharma to present itself as an expert in helping hospitals comply. The book situates the standards at the intersection of legitimate concern about undertreated pain, increasingly formal measurement, and commercial efforts that helped expand opioid prescribing.

Institutional Role and the New Standard

By the late 1990s, hospitals and doctors were being urged to treat pain with greater seriousness. The movement to designate pain as the fifth vital sign gave it status alongside blood pressure, heart rate, respiratory rate, and temperature. In 1999, the Joint Commission on Accreditation of Healthcare Organizations advanced that shift by approving mandatory standards for assessing and treating pain. Accreditation requirements translated a broad medical priority into an institutional expectation for hospitals.

The standards arose amid dissatisfaction with inadequate pain care. A widely discussed account of an older nursing-home resident left with only Tylenol for severe pain reflected a growing belief among health care experts that patients had long been undertreated, in part because of mistaken fears about addiction. That concern was real, but the question of what constituted adequate relief remained unresolved. The standards could require attention and assessment without settling how pain should be measured or what level of treatment was appropriate.

Measurement and Clinical Consequences

Pain assessment offered hospitals a way to formalize care, but the underlying measure was a patient’s subjective report. A numerical scale could make procedures easier to standardize while appearing more objective than it was: the same rating might describe experiences as different as labor and a stubbed toe, depending on the person’s tolerance. The book notes that reliance on pain scales did not correlate with improved patient outcomes and was associated with increased opioid prescribing and abuse.

The institutional pressure surrounding pain treatment also affected clinical practice. Doctors and hospitals were responding to expectations that pain be made a priority, as well as to consumer-satisfaction surveys and competition over patient ratings that could influence reimbursements. Dr. John Burton, head of emergency medicine for Carilion Clinic, later recalled that physicians had been told to take pain more seriously; in his account, prescribing rose without a sufficient understanding of the consequences. He also recalled believing that a two-week supply of opioid pills could not lead to addiction, a belief he recognized as wrong. These accounts illustrate the gap between adopting a standard and knowing how its application would affect patients.

Purdue Pharma and the Opportunity in Compliance

Purdue Pharma recognized the accreditation requirements as a commercial opportunity. In a 2000 budget plan, the company described the prospect of offering value-added services as pain experts and helping hospitals meet the Joint Commission’s requirements through assessment and management materials. The standards thus became not only a clinical obligation for hospitals but also a setting in which a drug company could position its products, expertise, and branded resources as solutions to an institutional need.

Purdue Pharma planned $300,000 in OxyContin-branded scroll pens, $225,000 in resource binders, and $290,000 in wall charts and clipboards bearing the message Pain: The Fifth Vital Sign. The materials linked a formal hospital priority to the company’s promotional presence in clinical settings. The book does not treat the accreditation body as the sole cause of opioid prescribing; rather, it shows how a standard adopted to address undertreated pain could be taken up within a larger system of reimbursement pressures, standardized assessment, and pharmaceutical marketing.

Significance and Limits

The Joint Commission on Accreditation of Healthcare Organizations occupies a consequential but bounded place in this account. Its standards helped make pain assessment and treatment a mandatory institutional concern, responding to a history of inadequate relief. Yet a requirement to assess pain did not itself establish a reliable objective measure, define adequate treatment, or guarantee better outcomes. The episode’s significance lies in that tension: a well-intentioned effort to improve care could become an incentive for more liberal prescribing when measurement, clinical judgment, and commercial promotion converged without a clear account of the risks.